Zai Lab Stock Today
| ZLAB Stock | USD 28.13 0.58 2.11% |
Performance11 of 100
| Odds Of DistressLess than 43
|
Zai Lab is trading at 28.13 as of the 28th of November 2024, a 2.11 percent increase since the beginning of the trading day. The stock's open price was 27.55. Zai Lab has about a 43 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Zai Lab are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China. The company has 107.45 M outstanding shares of which 4.66 M shares are at this time shorted by private and institutional investors with about 4.97 trading days to cover. More on Zai Lab
Moving together with Zai Stock
| 0.61 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Zai Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Zai Stock Highlights
| President Development | Rafael MD |
| Thematic Idea | Cancer Fighters (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Zai Lab (ZLAB) is traded on NASDAQ Exchange in USA. It is located in Jinchuang Plaza, Shanghai, China, 201210 and employs 2,175 people. Zai Lab is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.96 B. Zai Lab conducts business under Biotechnology sector and is part of Health Care industry. The entity has 107.45 M outstanding shares of which 4.66 M shares are at this time shorted by private and institutional investors with about 4.97 trading days to cover.
Zai Lab currently holds about 1.26 B in cash with (198.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.1.
Check Zai Lab Probability Of Bankruptcy
Ownership AllocationZai Lab retains a total of 107.45 Million outstanding shares. 30% of Zai Lab outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Zai Ownership Details
Zai Lab Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Zai Lab market risk premium is the additional return an investor will receive from holding Zai Lab long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1257 | |||
| Jensen Alpha | 0.5443 | |||
| Total Risk Alpha | 0.0015 | |||
| Sortino Ratio | 0.1189 |
Zai Stock Against Markets
Zai Lab Corporate Management
| Peter Huang | Chief Officer | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Joshua Smiley | Chief Officer | Profile | |
| Frazor III | Chief Sec | Profile | |
| Christine Chiou | Senior Relations | Profile | |
| Harald MD | Autoimmune Neuroscience | Profile |
Already Invested in Zai Lab?
The danger of trading Zai Lab is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zai Lab is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zai Lab. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zai Lab is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zai Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zai Lab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zai Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zai Lab Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zai Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Zai Stock refer to our How to Trade Zai Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zai Lab. If investors know Zai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zai Lab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zai Lab is measured differently than its book value, which is the value of Zai that is recorded on the company's balance sheet. Investors also form their own opinion of Zai Lab's value that differs from its market value or its book value, called intrinsic value, which is Zai Lab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zai Lab's market value can be influenced by many factors that don't directly affect Zai Lab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zai Lab's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zai Lab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zai Lab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.